explore -WSS

explore

author：knowledge 2025-09-27 22:47:38 - browse：5457

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： ALS advocates say criticism of new drugs misses bigger picture

entertainment

WSS

Cigna to pay $172 million to settle Medicare Advantage fraud probe

A new House health package & hospitals’ new site

Listen: Biogen's potential pivot, & Illumina's next chapter

The (many) problems with a new study criticizing cancer screening

How generative AI is inspiring dreams of a health data revolution

Ionis has late

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

Listen: Who gets the credit for GLP

The cancer drug shortage isn’t new — and neither are the solutions

A rare thyroid diagnosis led to unexpected, all

DIEP, the 'gold standard' of breast reconstruction, is under threat

Illumina names Agilent executive as new CEO

Affirmative action in medical school literally saved lives

The (many) problems with a new study criticizing cancer screening

Malaria cases in Florida and Texas: Here’s what you need to know

House transparency, PBM reform bill gains bipartisan support

entertainment

Medicaid rebukes states for mistakenly disenrolling children

A rare thyroid diagnosis led to unexpected, all

Medicare drug price negotiation program allowed for now

A rare thyroid diagnosis led to unexpected, all

Advances in CAR

Shingles, which affected Dianne Feinstein, is on the rise

leisure time

leisure time

entertainment

Wikipedia